$SLS 196M Shares Float / $80 Per SLS Share is only $15.6B
and that is Less than Half what Big Pharma will be Buying SLS For...
as others have pointed out many times, there have been and are No Job Openings at SLS
--- 13 FTE ' s and an IMMINENT P3 Result - NO Hiring
--- Does Everyone recall, Angie stating they have had ongoing Contacts with multiple Pharma's, and that he would Update the public when he has something Concrete.
$MRK Knows GPS is worth at Least 10B just for PR/ROC and MESO
TERM Sheets are already ready for Ink - Just waiting on the P3 Results.
- Elahere $IMGN achieved a MOS of 16.46 months for Pr/ROC and was bought by $ABBV for $10.1B - GPS +Keytruda achieved a Phase 1/2 MOS Result of 18.4 Months in the same exact patient setting.
Gps Extends Patent Life for $KEYTRUDA or $OPDIVO for another 10 YEARS
$IMGN $SLS Be Holding when the 80th EVENT PR is ANNOUNCED.
Expect a 2x 3x+ Move and the share Price will continue CLIMBING.
Gps is truly worth Several Tens of billions to big Pharma.
-- discussion regarding GPS WT1 Value
-- Gps + Pembro/Keytruda Phase 2 Trial Results - achieved Longer Survival for PR/ROC Patients than Elahere/ $IMGN which $ABBV bought for $10.1B
Elahere MOS of 16.46 MONTHS / GPS Key 18.4 MONTHS.
- Just this 1 Direct Market Comp at $10B
GPS is worth Tens of Billions to big Pharma.
Even the $MRK Dr. co-authoring the Final P2 DATA, stated Gps warranted further P3 Trials, - this is a massively bullish in Medspeak.
$ABBV $IMGN $LLY $PFE $SLS Volume just crossed 5 million shares in first 2.5 hours of trading.
Big Institutional funds gobbling up every loose share before the next PR Hits. ✌️❤️🩹🙏
$IMGN $LLY $PFE $SLS $ABBV AbbVie will make a move before the bidding war starts. I see them coming before the GPS Regal Pivotal Registrational phase 3 data comes out. Ventoclax is $1.9 Billion dollar annual blockbuster for AbbVie.
Merck has already done multiple studies with SLS GPS+ Keytruda, with Keytruda patent expiring in 2028. Merck will be part of the bidding war unless AbbVie picks them up pre data read out! ✌️❤️🩹🙏
$IMGN $LLY $PFE $SLS Greg, PFE is # 1 suitor on my list followed by AbbVie. AbbVie Ventoclax will be Obsolete after GPS approval. Pfizer has made all the moves and CEO Dr. Bourla is a close friend of Sellas CEO Dr. Angelos Stergiou. 👇✌️❤️🩹🙏
$SLS $LLY $PFE CEO Explaining approximately 12,000 AML CR2 patients will be Eligible for GPS Immunotherapy each year EU/US/J.
xCCO estimated Minimum Pricing comps of $280K / $300K Rev Per Patient Year 1
Infinite Dosing Regime - Year 2 $110K Rev.
- Just AMLCR2/3 is worth Nearly $75 Per Share to Big Pharma
and You can't have any CR2/3 Value without Applying further Value for CR1 / Post Stem Cell Transplant, + MESO and PRROC.
- GPS +Keytruda Phase 2 PR/ROC MOS of 18.4 Months was better than Elahere $IMGN that got bought for $10.1B ... as a single comp.
$SLS 125 Million+ Cash on hand per last 10K filing.
Gps will be CURATIVE in over 20+ WT1 cancer Types.
GPS Ad Infinitum Dosing will generate over $50 Billion+ annually for Big Pharmaceutical Suitors.
GPs has already proven effective in Mesothelioma and Platinum Resistant Ovarian Cancer settings, achieving better Phase 2 Combination trial Results with Keytruda $MRK - MOS of 18.4 months - than, Elahere $IMGN 16.4 Months, which earned FDA Approval and was bought by $ABBV for $10.1B - this is just 1 comp worth $10B.
SLS009 has already shown 4 times better response in phase 2b than current SOC.
Bidding war is coming $280 Per share. Don’t step over hundred dollar 💵 Bills to pick up Pennie’s. Hold with Conviction. ✌️🙏❤️🩹
$SLS PSA: $MRK has been waiting, like the rest of us, expected data already, problem is patients are living too long...
Here is MRK Dr. Julie Cohen who co-authored the GPS Keytruda P2 Publication, saying GPS + Key will work even better* in Remission Envoronments.
* GPS Key P1/2 Mos of 18.4 months is better than Elahere 16.4 months in PROC $IMGN that got bought for $10.1B
@sean1122 MRK has been waiting, like the rest of us, expected data already, problem is patients are living too long...
PS here is MRK Dr. Julie Cohen who co-authored the GPS Keytruda P2 Publication, saying GPS + Key will work even better* in Remission Envoronments. * GPS Key Mos of 18.4 months is better than Elahere 16.4 mo nths in PROC $IMGN that got bought for $10.1B
$SLS $MRK the $IMGN $ABBV - $10.1B Buyout for Elahere is a $10.1B Comp for GPS
- $10B Just for Platinum Resistant Ovarian Cancer.
- Elahere achieved a MOS of 16.46 Months, with Some Severe Side Effects, actually Blinds Patients.
Gps + Key MOS of 18.4 Months is better, with Zero Additional Toxicity.
- $TERN $6.7B Buyout is a Direct Comp just for SLS009 - Phase 2B Data Presented at ASH Dec 2025 for AML High-Risk TP53/ASXL1+ ...
SLS Shares Sub $40 represents the Investment Opportunity of a Lifetime.
ALL Gps needs for Fda Approval, per the Pre Approved SAP, is a HR of .636 and its a done deal.
$SLS $SLS Gps+Keytruda $MRK achieved better Median Overall Survival (18.4) data than Fda approved Relocorilant (16) $CORT and Better than Fda approved Elahere $IMGN (16.4) which $ABBV bought for $10.1B.
$SLS These are the Days to Be Loading in as many as you can Nut Sack Up.
--- How long is too long to wait for 40x Returns?
Most of the inch thick mile wide tools on this board, think tomorrow is --- but Smart Long, Institutional Fund Analysts Live for these Massive Near Term Catalysts.
- Could be ANY Day Now Here.
Gps worth $40B Plus the Instant the GPs Phase 3 Registrational Results are announced - and we are conceivably in the ANY DAY NOW Zone.
SLS Valuation:
• GPs 12,500 AML CR2/3 Patients Each Year
• GPs 40,000 AML CR1 Patients Each Year
+ 100,000 AML Patients Currently in Remission who'll Immediately benefit from and be Eligible for Gps
• xCCo Estimated $280K Revenue Per Patient Year 1
• Ad-Infinite Multi-year Dosing Regime Compounds Rev.
• $110K Per Patient Year 2 Revenue.
• Gps WT1+ PR/ROC $IMGN $ABBV $10.1B BO Comp
• 1M WT1+ patients Diagnosed Globally each year
• SLS009 AML-MR Direct Comp $GILD $4.9B BO.
rNPV for CR2/3 - this is the TAM - just for CR2/3
$SLS is worth $40B Plus the Instant the GPs Phase 3 Registrational Results are announced - and we are conceivably in the ANY DAY NOW Zone.
SLS Valuation:
• GPs 12,500 AML CR2/3 Patients Each Year
• GPs 40,000 AML CR1 Patients Each Year
+ 100,000 AML Patients Currently in Remission who'll Immediately benefit from and be Eligible for Gps
• xCCo Estimated $280K Revenue Per Patient Year 1
• Ad-Infinite Multi-year Dosing Regime Compounds Rev.
• $110K Per Patient Year 2 Revenue.
• Gps WT1+ PR/ROC $IMGN $ABBV $10.1B BO Comp
• 1M WT1+ patients Diagnosed Globally each year
• SLS009 AML-MR Direct Comp $GILD $4.9B BO.
rNPV for CR2/3
